Abstract: Systemic sclerosis (SSc), also known as scleroderma, is an unusual connective tissue disease that SSc preferentially affects mostly women, but still can affects males too, and generally begins in between 45 and 65 years. This review will focus on the Pathogenesis of SSc, also intended to discuss the treatment approaches of this dermatological disease, in addition aiming to emphasize the potential role of the genetics, epithelium, fibroblasts and immune system in the pathogenesis of SSc. A comprehensive search was performed to identify studies published in PubMed and the Cochrane database up to December 2016, in English language and involving human subject only and recently published abstracts were also reviewed our search was for detection of studies that discussing the pathogenesis and treatment of SSc. The pathogenesis of SSc is intricate and appears to include endothelium, epithelium, fibroblasts and immunological mediators, leading to dysregulated vascular renovation and, eventually, vasculopathy. Endothelial cell injury is an early and probably starting event, however the exact aetiology stays uncertain. Although the pathogenesis of SSc stays evasive, we are learning more about the disease systems, which will assist detectives in developing more targeted therapies for this devastating disease. A coherent unifying hypothesis to discuss the varied symptoms of SSc, including its vascular, immune, and fibrotic aspects, extremely comprehensive and could discuss the pathogenesis behind the SSc.
Keywords: Systemic sclerosis (SSc), Pathogenesis, and Treatment.
Title: Overview of Scleroderma (Systemic Sclerosis), Pathogenesis, and Treatment
Author: Hind Sajdi Alatawi, Alshaymaa Abdulrahman Alshaikh, Arwa Meshal Alshaikh
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
